GNRH1 and pregnancy disorder: The retrospective cohort study of Wang et al., which further expanded the sample size (1589 live-born infants), showed that neonatal outcomes and the risk of congenital malformations were similar between the PPOS (Utrogestan) and short GnRH antagonist groups (1.52% vs. 1.63%) (23).